226 related articles for article (PubMed ID: 34433435)
1. FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells.
Jia T; Jacquet T; Dalonneau F; Coudert P; Vaganay E; Exbrayat-Héritier C; Vollaire J; Josserand V; Ruggiero F; Coll JL; Eymin B
BMC Biol; 2021 Aug; 19(1):173. PubMed ID: 34433435
[TBL] [Abstract][Full Text] [Related]
2. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
[TBL] [Abstract][Full Text] [Related]
3. A VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells.
Abou Faycal C; Gazzeri S; Eymin B
Sci Rep; 2019 Jan; 9(1):336. PubMed ID: 30674935
[TBL] [Abstract][Full Text] [Related]
4. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.
Mole S; Faizo AAA; Hernandez-Lopez H; Griffiths M; Stevenson A; Roberts S; Graham SV
J Gen Virol; 2020 May; 101(5):523-532. PubMed ID: 32182205
[TBL] [Abstract][Full Text] [Related]
7. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
8. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.
Gout S; Brambilla E; Boudria A; Drissi R; Lantuejoul S; Gazzeri S; Eymin B
PLoS One; 2012; 7(10):e46539. PubMed ID: 23071587
[TBL] [Abstract][Full Text] [Related]
9. SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma.
Liu H; Gong Z; Li K; Zhang Q; Xu Z; Xu Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):75. PubMed ID: 33602301
[TBL] [Abstract][Full Text] [Related]
10. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
[TBL] [Abstract][Full Text] [Related]
11. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
12. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of a splicing factor through a nuclear kinase-kinase complex.
Aubol BE; Keshwani MM; Fattet L; Adams JA
Biochem J; 2018 Feb; 475(3):677-690. PubMed ID: 29335301
[TBL] [Abstract][Full Text] [Related]
14. SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma.
Yang S; Jia R; Bian Z
Biochim Biophys Acta Mol Cell Res; 2018 Sep; 1865(9):1161-1172. PubMed ID: 29857020
[TBL] [Abstract][Full Text] [Related]
15. SRSF3: Newly discovered functions and roles in human health and diseases.
More DA; Kumar A
Eur J Cell Biol; 2020 Aug; 99(6):151099. PubMed ID: 32800280
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway.
Thorsen K; Mansilla F; Schepeler T; Øster B; Rasmussen MH; Dyrskjøt L; Karni R; Akerman M; Krainer AR; Laurberg S; Andersen CL; Ørntoft TF
Mol Cell Proteomics; 2011 Jan; 10(1):M110.002998. PubMed ID: 20938052
[TBL] [Abstract][Full Text] [Related]
17. The GAUGAA Motif Is Responsible for the Binding between circSMARCA5 and SRSF1 and Related Downstream Effects on Glioblastoma Multiforme Cell Migration and Angiogenic Potential.
Barbagallo D; Caponnetto A; Barbagallo C; Battaglia R; Mirabella F; Brex D; Stella M; Broggi G; Altieri R; Certo F; Caltabiano R; Barbagallo GMV; Anfuso CD; Lupo G; Ragusa M; Di Pietro C; Hansen TB; Purrello M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562358
[TBL] [Abstract][Full Text] [Related]
18. A collagen Vα1-derived fragment inhibits FGF-2 induced-angiogenesis by modulating endothelial cells plasticity through its heparin-binding site.
Jia T; Vaganay E; Carpentier G; Coudert P; Guzman-Gonzales V; Manuel R; Eymin B; Coll JL; Ruggiero F
Matrix Biol; 2020 Dec; 94():18-30. PubMed ID: 32682018
[TBL] [Abstract][Full Text] [Related]
19. Distinct mechanisms govern the phosphorylation of different SR protein splicing factors.
Long Y; Sou WH; Yung KWY; Liu H; Wan SWC; Li Q; Zeng C; Law COK; Chan GHC; Lau TCK; Ngo JCK
J Biol Chem; 2019 Jan; 294(4):1312-1327. PubMed ID: 30478176
[TBL] [Abstract][Full Text] [Related]
20. PKCε activation promotes FGF-2 exocytosis and induces endothelial cell proliferation and sprouting.
Monti M; Donnini S; Morbidelli L; Giachetti A; Mochly-Rosen D; Mignatti P; Ziche M
J Mol Cell Cardiol; 2013 Oct; 63():107-17. PubMed ID: 23880610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
